Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
20.14
+0.69 (3.55%)
At close: Nov 6, 2026, 4:00 PM EST
20.40
+0.26 (1.29%)
After-hours: Nov 6, 2026, 7:30 PM EST
Amneal Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,196 | 3,019 | 2,794 | 2,394 | 2,212 | 2,094 | |
Revenue Growth | 8.88% | 8.05% | 16.73% | 8.20% | 5.67% | 5.08% |
Cost of Revenue | 1,915 | 1,890 | 1,778 | 1,541 | 1,421 | 1,310 |
Gross Profit | 1,281 | 1,128 | 1,016 | 852.87 | 791.46 | 783.95 |
Selling, General & Admin | 573.91 | 526.85 | 476.54 | 429.78 | 399.7 | 365.5 |
Research & Development | 169.97 | 186.15 | 190.61 | 163.85 | 195.69 | 201.85 |
Other Operating Expenses | -8.87 | -5.24 | - | -1.14 | -3.96 | - |
Operating Expenses | 735.01 | 707.76 | 667.15 | 592.49 | 591.43 | 567.35 |
Operating Income | 545.52 | 420.7 | 348.36 | 260.38 | 200.03 | 216.6 |
Interest Expense | -223.55 | -241.09 | -258.6 | -210.63 | -158.38 | -136.33 |
Currency Exchange Gain (Loss) | -14.36 | 7.64 | -6.85 | 1.67 | -12.36 | -0.36 |
Other Non Operating Income (Expenses) | -10.35 | 9.93 | -42.66 | 5.12 | 17.83 | 15.33 |
EBT Excluding Unusual Items | 297.26 | 197.18 | 40.26 | 56.54 | 47.13 | 95.25 |
Merger & Restructuring Charges | -37.23 | -4.21 | -2.36 | -1.75 | -2.13 | -9.91 |
Gain (Loss) on Sale of Assets | - | - | 3.76 | - | - | - |
Asset Writedown | -20.05 | -22.78 | -0.92 | -36.13 | -11.11 | -22.69 |
Legal Settlements | -15.25 | 0.39 | -96.69 | -1.82 | -269.93 | -25 |
Other Unusual Items | -3.27 | -31.37 | 0.93 | -26.31 | -1.02 | -10.57 |
Pretax Income | 221.46 | 139.21 | -55.01 | -40.27 | -248.13 | 31.37 |
Income Tax Expense | 11.97 | 11.28 | 18.86 | 8.45 | 6.66 | 11.2 |
Earnings From Continuing Operations | 209.49 | 127.93 | -73.88 | -48.72 | -254.79 | 20.17 |
Minority Interest in Earnings | -76.19 | -55.88 | -43.01 | -35.27 | 124.8 | -9.55 |
Net Income | 133.3 | 72.06 | -116.89 | -83.99 | -129.99 | 10.62 |
Net Income to Common | 133.3 | 72.06 | -116.89 | -83.99 | -129.99 | 10.62 |
Net Income Growth | 2159.31% | - | - | - | - | -88.33% |
Shares Outstanding (Basic) | 321 | 313 | 309 | 176 | 151 | 149 |
Shares Outstanding (Diluted) | 333 | 325 | 309 | 176 | 151 | 152 |
Shares Change | 4.13% | 5.12% | 75.42% | 16.69% | -0.58% | 1.95% |
EPS (Basic) | 0.41 | 0.23 | -0.38 | -0.48 | -0.86 | 0.07 |
EPS (Diluted) | 0.40 | 0.22 | -0.38 | -0.48 | -0.86 | 0.07 |
EPS Growth | 2380.01% | - | - | - | - | -88.52% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 38.42 | 241.15 | 234.76 | 298.78 | 16.3 | 190.88 |
Free Cash Flow Per Share | 0.12 | 0.74 | 0.76 | 1.70 | 0.11 | 1.26 |
Gross Margin | 40.07% | 37.38% | 36.35% | 35.63% | 35.77% | 37.44% |
Operating Margin | 17.07% | 13.94% | 12.47% | 10.88% | 9.04% | 10.35% |
Profit Margin | 4.17% | 2.39% | -4.18% | -3.51% | -5.88% | 0.51% |
Free Cash Flow Margin | 1.20% | 7.99% | 8.40% | 12.48% | 0.74% | 9.12% |
EBITDA | 739 | 644.27 | 584.55 | 489.78 | 440.21 | 450 |
EBITDA Margin | 23.13% | 21.34% | 20.92% | 20.46% | 19.90% | 21.49% |
D&A For EBITDA | 193.48 | 223.57 | 236.19 | 229.4 | 240.18 | 233.41 |
EBIT | 545.52 | 420.7 | 348.36 | 260.38 | 200.03 | 216.6 |
EBIT Margin | 17.07% | 13.94% | 12.47% | 10.88% | 9.04% | 10.35% |
Effective Tax Rate | 5.40% | 8.10% | - | - | - | 35.70% |
Advertising Expenses | - | 42 | 34.4 | 12.4 | 16.8 | - |